AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...

AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical significance for its primary endpoint in AL amyloidosis, although it showed promise ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

Following a successful patent defense case upheld by China’s IP authority, AstraZeneca invested nearly 9 billion yuan ($1.24 billion) to establish two global R&D centres in Beijing and Shanghai, said ...